Eli Lilly briefly surpassed a $1 trillion market valuation, marking a historic milestone as the first drugmaker to achieve this level. The company's rapid ascent is driven by soaring demand for its incretin-based drugs, Mounjaro and Zepbound, which target type 2 diabetes and obesity. These two medications have become the primary growth drivers for Lilly, with revenues in the most recent quarter showing dramatic year-over-year increases. The combined sales of Mounjaro and Zepbound have now outpaced those of other leading pharmaceuticals, establishing Lilly as the top-selling drugmaker worldwide.